Association between CYP2E1 polymorphisms and susceptibility to prostate cancer

European Journal of Cancer Prevention

Volumn 12, Issue 3, 2003, Pages 205-211

  Ferreira, P M ^a,c   Medeiros, R ^a,c   Vasconcelos, A ^a   Costa, S ^a   Pinto, D ^a   Morais, A ^b   Oliveira, J ^b   Lopes, C ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Unit of Molecular Oncology   (Portugal)

^c Unit of Molecular Oncology   (Portugal)

Author keywords

Chromosome 10; CYP2E1; Genetic polymorphisms; PCR RFLP; Prostate cancer

Indexed keywords

CYTOCHROME P450 2E1;

ADULT; AGED; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP2E1; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PORTUGAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; STATISTICS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037502788     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200306000-00007     Document Type: Article

References (77)

1. Adami HO, McLaughlin JK, Hsing AW, et al. (1992). Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control 3:419-425.
2. Adami HO, Bergstrom R, Enghelm G, et al. (1996). A prospective study of smoking and risk of prostate cancer. Int J Cancer 67:764-768.
3. Bartsch H, Nair U, Risch A, et al. (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9:3-28.
4. Bergerheim US, Kunimi K, Collins VP, et al. (1991). Deletion mapping of chromosomes 8, 10 and 16 in human prostatic carcinoma. Genes Chromosom Cancer 3:215-220.
5. Beffetta P, Pearce N (1999). Epidemiological Studies on Genetic Polymorphisms: Study Design Issues and Measures of Occurrence and Association. IARC Scientific Publication No. 148. IARC: Lyon; pp. 97-108.
6. Bouchardy C, Hirvonen A, Coutelle C, et al. (2000). Role of dehydregenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 87:734-740.
7. Cannon L, Bishop DT, Skolnick M, et al. (1982). Genetic epidemiology of prostate cancer in the Utah Mormon Genealogy. Cancer Surv 1:4-69.
8. Carrière V, Berthou F, Baird S, et al. (1996). Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 6:203-211.
9. Carroll PR, Lee KL, Fuks ZY, et al. (2001). Cancer of the prostate. In: Devita VT, Hellman S, Resenberg AS (editors) Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott-Raven Publishers; pp. 1418-1427.
10. Carter BS, Beaty TH, Steinberg GD, et al. (1992). Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367-3371.
11. Carter BS, Bova GS, Beaty TH, et al. (1993). Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150:797-802.
12. Daniell HW (1995). A worse prognosis for smokers with prostate cancer. J Urol 154:153-157.
13. Dennis LK, Hayes RB (2001). Alcohol and prostate cancer. Epidemiol Rev 23:110-114.
14. d'Errico A, Malats N, Vineis P, et al. (1999). Review of Studies of Selected Metabolic Polymorphisms and Cancer. IARC Scientific Publication No. 148. IARC: Lyon; pp. 323-93.
15. Eagle LR, Yin X, Brothman AR, et al. (1995). Mutation of the MXI1 gene in prostate cancer. Nature Genet 9:249-255.
16. Eichholzer M, Stahelin H, Ludin E, et al. (1999). Smoking, plasma vitamins C, E, retinol, and fatal prostate cancer: seventeen-year follow-up of prospective Basel study. Prostate 38:189-198.
17. Ferlay J, Bray F, Pisani P, et al. (2001). Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5. IARC Press: Lyon.
18. Field AE, Colditz GA, Willet WC, et al. (1994). The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 79:1310-1316.
19. George DJ, Shepard TF, Giovannuci MJ, et al. (2001). PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 10:411-412.
20. Gleason DF (1990). Histological grading of prostatic carcinoma. In: Bostwick DG (editor): Pathology of the Prostate. New York: Churchill Livingstone; pp. 83-93.
21. Gray IC, Philips SA, Lee SJ, et al. (1995). Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 55:4800-4803.
22. Hayashi S-I, Watanabe J, Kawajiri K (1991). Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 110:559-565.
23. Hecht SS, Hoffmann D (1988). Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 9:875-884.
24. Hickey K, Do K-A, Green A (2001). Smoking and prostate cancer. Epidemiol Rev 23:115-125.
25. Hildsheim A, Anderson L, Chen C-J, et al. (1997). CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 89:1207-1212.
26. Hirayama T (1992). Life-style and cancer: from epidemiologic evidence to public behavior change to mortality reduction of target cancers. J Natl Cancer Inst Monogr 12:65-74.
27. Hirvonen A, Husgafvel-Pursiainen K, Antila S, et al. (1993). The human CYP2E1 gene and lung cancer: Dral and Rsal restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14:85-88.
28. Hoffmann D, Hecht SS (1985). Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions. Cancer Res 45:935-944.
29. Hsing AW, McLaughlin JK, Schuman LM, et al. (1990). Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood cohort study. Cancer Res 50:6836-6840.
30. Hsing AW, McLaughlin JK, Hrubec Z, et al. (1991). Tobacco use and prostate cancer: 26-year follow-up of US veterans. Am J Epidemiol 133:437-441.
31. Isaacs WB, Bova GS (1998). Prostate cancer. In: Vogelstein B, Kinzler K (editors): The Genetic Basis of Human Cancer. New York: McGraw Hill; pp. 653-660.
32. Jensen OM, Paine SL, McMichael AJ, et al. (1996). Alcohol. In: Schottenfeld D, Fraumeni JF Jr (editors): Cancer Epidemiology and Prevention, 2nd edn. Oxford University Press: New York; pp. 290-318.
33. Kato S, Shields PG, Caporaso NE, et al. (1992). Cytochrome P450IIE1 genetic polymorphisms, racial variation and lung cancer risk. Cancer Res 52:6712-6715.
34. Kato S, Onda M, Matsukura N, et al. (1996). Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. Cancer 77:1654-1661.
35. Kolonel LN (2001). Fat, meat, and prostate cancer. Epidemiol Rev 23:72-81.
36. Kunimi K, Bergerheim US, Larsson IL, et al. (1991). Allelotyping of human prostatic adenocarcinoma. Genomics 11:530-536.
37. Kupeli B, Soygur T, Aydos K, et al. (1997). The role of cigarette smoking in prostatic enlargement. Br J Urol 80:201-204.
38. Le Marchand L, Sivaraman L, Pierce L, et al. (1998). Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58:4858-4863.
39. Le Marchand L, Wilkinson GR, Wilkens LR (1999). Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 8:495-500.
40. Lieber CS (1997). Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 77:517-544.
41. Little J, Bradley L, Bray MS, et al. (2002). Reporting, appraising, and integrating data on genotype prevalence and gene-diseases associations. Am J Epidemiol 156:300-310.
42. Lucas D, Menez C, Girre C, et al. (1995). Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 5:298-304.
43. MacBride OW, Umeno M, Belboin HV, et al. (1987). A Taql polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res 15:10071.
44. Matsumoto H, Matsubayashi K, Fukui Y (1996). Evidence that cytochrome P-4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4-methyl pyrazole on ethanol elimination in the perfused rat liver. Alcohol Clin Exp Res 20:12A-16A.
45. Medeiros R, Morais A, Vasconcelos A, et al. (2002a). The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern Europe population. J Hum Genet 47:413-418.
46. Medeiros R, Morais A, Vasconcelos A, et al. (2002b). Linkage between polymorphisms in the prostate-specific antigen ARE1 gene region, prostate cancer risk, and circulating tumour cells. Prostate 53:88-94.
47. Medeiros R, Morais A, Vasconcelos A, et al. (2002c). Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 11:343-350.
48. Michaud DS, Augustsson K, Rimm EB, et al. (2001). A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 12:557-567.
49. Müllenbach R, Lagoda PJ, Welter C (1989). An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 5:391.
50. Murata M, Watanabe M, Yamanaka M, et al. (2001). Genetic Polymorphisms in cytochreme P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 165:171-177.
51. Narod S, Dupont A, Cusan L, et al. (1995). The impact of family history on early detection of prostate cancer. Nature Med 1:99-101.
52. Nelson WG, DeWese TL, DeMarzo AM (2002). The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 21:3-16.
53. Nishimoto I, Hanaoka T, Sugimura H, et al. (2000). Cytochrome P4502E1 polymorphism in gastric cancer in Brazil: case-control studies of Japanese Brazilians and non-Japanese Brazilians. Cancer Epidemiol Biomarkers Prev 9:675-680.
54. Persson I, Johnson I, Bergling H, et al. (1993). Genetic polymorphisms of cytochrome P450 2E1 in a Swedish population: relation to incidence of lung cancer. FEBS Lett 319:207-211.
55. Pisansky TM, Kahn M, Rasp G, et al. (1997). A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer 79:337-344.
56. Powell H, Kitteringham NR, Pirmohamed M, et al. (1998). Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 8:411-421.
57. Rodriguez C, Tatham LM, Thun MJ, et al. (1997). Smoking and fatal prostate cancer in a large cohort of adult men. Am J Epidemiol 145:466-475.
58. Scanlan RA (1983). Formation and occurrence of nitrosamines in food. Cancer Res 45:2435s-2440s.
59. Schiffman M, Bauer H, Hoover R, et al. (1993). Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:958-964.
60. Sesso HD, Paffenbarger Jr RS, Lee I-M (2001). Alcohol consumption and risk of prostate cancer: the Harvard alumni health study. Int J Epidemiol 30:749-755.
61. Sharpe CR, Siemiatychi J (2001). Joint effects of smoking and body mass index on prostate cancer risk. Epidemiology 12:546-551.
62. Stephens EA, Taylor JA, Kaplan N, et al. (1994). Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 4:185-192.
63. Tan W, Song N, Wang GQ, et al. (2000). Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarkers Prev 9:551-556.
64. Tonnesen H, Moller H, Andersen JR, et al. (1994). Cancer morbidity in alcohol abusers. Br J Cancer 69:327-332.
65. Uematsu F, Kikuchi H, Motmyia M, et al. (1991a). Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82:254-256.
66. Uematsu F, Kikuchi H, Ohmachi T, et al. (1991b). Two common RFLPs of CYP2E gene. Nucleic Acids Res 19:2803.
67. Uematsu F, Kikuchi H, Abe T, et al. (1991c). Mspl polymorphism of the human CYP2E gene. Nucleic Acids Res 19:5797.
68. Uematsu F, Ikawa S, Kikuchi H, et al. (1994). Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics 4:58-63.
69. Umeno M, McBride OW, Yang CS, et al. (1988). Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 27:9006-9013.
70. Wang S-L, Lee H, Chen K-W, et al. (1999). Cytochrome P4502E1 genetic polymorphisms and lung cancer in a Taiwanese population. Lung Cancer 26:27-34.
71. Watanabe J, Hayash S-I, Nakachi K, et al. (1990). Pstl and Rsal RFLPs in complete linkage disequilibrium at the CYP2E1 gene. Nucleic Acids Res 18:7194.
72. Watanabe J, Hayashi S-I, Kawajiri K (1994). Different regulation and expression of the human CYP2E1 gene due to the Rsal in the 5′-flanking region. J Biochem 116:321-326.
73. Wu X, Shi H, Jiang H, et al. (1997). Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 18:967-973.
74. Wu X, Amos CI, Kemp BL, et al. (1998). Cytochrome P450 2E1 Dral polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev 7:13-18.
75. Yamazaki H, Inui Y, Yun C-H, et al. (1992). Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789-1794.
76. Yoo J-S, Guengerich FP, Yang CS (1988). Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 48:1499-1504.
77. Yu MW, Gladek-Yarborough A, Chiamprasert S, et al. (1995). Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 109:1266-1273.